Oncolix Inc. (fka ONCX)

[Rat Fink]

VERY SUCCESSFUL MD ANDERSON PRE-CLINICAL_TRIAL_OF_ONCOLIX_PROLANTA/G129R_http://nebula.wsimg.com/5542c0afba149bcb25b0b56a5099a065?AccessKeyId=D34B304F5C474C27E878&disposition=0&alloworigin=1

CONCLUSION (LOWER LEFT-HAND CORNER):

G129R functions as a molecular
antagonist to tumor-associated PRL by inducing
adaptive autophagic cell death in human ovarian cancer.
These preclinical findings reveal the novelty of G129R as
an adjuvant therapy for ovarian cancer.

CONCLUSIONS (LOWER RIGHT-HAND CORNER)

1. Prolactin antagonist, G129R, inhibits ovarian cancer growth and
progression;
2. PRLR is required for G129R induced autophagy;
3. PEA-15 mediates autophagic cell death induced by blocking
PLR/PRLR signaling;


PROLANTA™ (REFERENCED IN THE SCIENTIFIC LITERATURE AS G129R: https://www.oncolixbio.com/prolanta-structure.html


PROLANTA™ DESCRIPTION: https://www.oncolixbio.com/home.html